Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a biopharmaceutical company focused on developing and commercializing therapies to treat autoimmune diseases. The company's flagship product, Lupkynis, is used to treat lupus nephritis, a serious kidney inflammation caused by lupus. Aurinia competes with other biopharmaceutical companies like TG Therapeutics, Axsome Therapeutics, Karyopharm Therapeutics, Ocular Therapeutix, and Aptose Biosciences.
AUPH's Return on Invested Capital (ROIC) is 15.53%, which is higher than its Weighted Average Cost of Capital (WACC) of 11.01%. This results in a ROIC/WACC ratio of 1.41, indicating that Aurinia is generating returns above its cost of capital. This is a positive indicator for investors, as it suggests efficient capital utilization.
In comparison, TG Therapeutics (TGTX) has a ROIC of 13.54% and a WACC of 12.37%, resulting in a ROIC/WACC ratio of 1.10. While TGTX is also generating returns above its cost of capital, its efficiency is lower than AUPH's. This makes Aurinia more attractive in terms of capital efficiency.
Other peers like Axsome Therapeutics (AXSM), Karyopharm Therapeutics (KPTI), Ocular Therapeutix (OCUL), and Aptose Biosciences (APTO) have negative ROIC to WACC ratios. For instance, AXSM has a ROIC of -43.95% and a WACC of 5.95%, leading to a ROIC/WACC ratio of -7.38. This indicates these companies are not generating returns above their cost of capital.
Aurinia Pharmaceuticals stands out with the highest ROIC to WACC ratio among its peers. This suggests that AUPH is effectively utilizing its capital to generate superior returns relative to its cost, making it a potentially more attractive investment option.
